Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Subscribe To Our Newsletter & Stay Updated